{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:15:27Z","timestamp":1793812527431,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction\n\n<\/jats:title>\n                <jats:p>Ataluren is a relatively new treatment for male patients with Duchenne muscular dystrophy (DMD) due to a premature stop codon. Long-term longitudinal data as well as efficacy data on non-ambulant patients are still lacking. Here we present the results from a long-term follow-up study of all DMD patients treated with ataluren and followed at the Queen Silvia Children\u2019s Hospital in Gothenburg, Sweden, with focus on the evolution of patients\u2019 upper motor and respiratory function over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective longitudinal case-series study of all male DMD patients treated with ataluren and followed at the Queen Silvia Children\u2019s Hospital in Gothenburg, Sweden, since 2008.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our eleven patients had a median exposure to ataluren of 2312\u00a0days which is almost a fourfold higher than previous studies. Loss of ambulation occurred at a median age of 13.2\u00a0years. Patients who lost ambulation prior to 13.2\u00a0years of age had received ataluren for 5\u00a0years, whereas patients who continued to be ambulatory after 13.2\u00a0years of age had received ataluren for 6.5\u00a0years until loss of ambulation or last follow-up if still ambulatory. Four of six non ambulatory patients had Performance of the Upper Limb scores above the expected mean values over time. All but one patient maintained a pulmonary decline above the expected over time. All ambulatory patients increased in their predicted forced vital capacity (FVC) with 2.8 to 8.2% annually. Following loss of ambulation, 5 of 6 patients declined in predicted FVC (%), with annual rate of decline varying from 1.8 to 21.1%. The treatment was safe and well tolerated throughout the follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first study to present long-term cumulative treatment outcomes over a median period of 6.3\u00a0years on ataluren treatment. Our results indicate a delay in loss of ambulation, as well as a slower decline in FVC and upper limb motor function even after loss of ambulation. We suggest that treatment with ataluren should be initiated as soon as the diagnosis is confirmed, closely monitored and, in case of sustainable benefit, continued even after loss of ambulation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-021-04700-z","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T16:53:52Z","timestamp":1633020832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long term treatment with ataluren\u2014the Swedish experience"],"prefix":"10.1186","volume":"22","author":[{"given":"Eva","family":"Michael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Sofou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Kroksmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1r","family":"Tulinius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"4700_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","volume":"155","author":"E Ciafaloni","year":"2009","unstructured":"Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009;155:380\u20135.","journal-title":"J Pediatr"},{"key":"4700_CR2","doi-asserted-by":"crossref","unstructured":"Pane M, Scalise R, Berardinelli A, D\u2019Angelo G, Ricotti V, Alfieri P, et al. Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul Disord. 2013;23:451\u20135.","DOI":"10.1016\/j.nmd.2013.02.012"},{"key":"4700_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391:451\u201361.","journal-title":"Lancet"},{"key":"4700_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393.","journal-title":"Lancet Neurol"},{"key":"4700_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","volume":"9","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Muntoni F, Osorio AN, Tulinius M, Buccella F, Morgenroth LP, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. 2020;9:341\u201360.","journal-title":"J Comp Eff Res"},{"key":"4700_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395\u2013402.","journal-title":"Hum Mutat"},{"key":"4700_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87\u201391.","journal-title":"Nature"},{"key":"4700_CR8","doi-asserted-by":"publisher","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B, B\u00f6nnemann C, Sampson J, Sweeney HL, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One. 2013;8:e81302.","journal-title":"PLoS One"},{"key":"4700_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50:477\u201387.","journal-title":"Muscle Nerve"},{"key":"4700_CR10","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489\u201398.","journal-title":"Lancet"},{"key":"4700_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, et al. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol. 2013;55:1038\u201345.","journal-title":"Dev Med Child Neurol"},{"key":"4700_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324\u201343.","journal-title":"Eur Respir J"},{"key":"4700_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.nmd.2013.11.014","volume":"24","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S, et al. Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord. 2014;24:201\u20136.","journal-title":"Neuromuscul Disord"},{"key":"4700_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ppul.23172","volume":"50","author":"OH Mayer","year":"2015","unstructured":"Mayer OH, Finkel RS, Rummey C, Benton MJ, Glanzman AM, Flickinger J, et al. Characterization of pulmonary function in Duchenne Muscular Dystrophy. Pediatr Pulmonol. 2015;50:487\u201394.","journal-title":"Pediatr Pulmonol"},{"key":"4700_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347\u201361.","journal-title":"Lancet Neurol"},{"key":"4700_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fped.2018.00316","volume":"6","author":"D Ebrahimi-Fakhari","year":"2018","unstructured":"Ebrahimi-Fakhari D, Dillmann U, Flotats-Bastardas M, Poryo M, Abdul-Khaliq H, Shamdeen MG, et al. Off-label use of ataluren in four non-ambulatory patients with nonsense mutation Duchenne muscular dystrophy: effects on cardiac and pulmonary function and muscle strength. Front Pediatr. 2018;6:316.","journal-title":"Front Pediatr"},{"key":"4700_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/cer-2019-0086","volume":"8","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Desguerre I, Guglieri M, Osorio AN, Kirschner J, Tulinius M, et al. Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. J Comp Eff Res. 2019;8:1187\u2013200.","journal-title":"J Comp Eff Res"},{"key":"4700_CR18","doi-asserted-by":"crossref","unstructured":"Pane M, Fanelli L, Mazzone ES, Olivieri G, D\u2019Amico A, Messina S, et al. Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test. Neuromuscul Disord. 2015;25:749\u201353.","DOI":"10.1016\/j.nmd.2015.07.009"},{"key":"4700_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"EK Henricson","year":"2013","unstructured":"Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48:55\u201367.","journal-title":"Muscle Nerve"},{"key":"4700_CR20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","volume":"320","author":"JR Mendell","year":"1989","unstructured":"Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne\u2019s muscular dystrophy. N Engl J Med. 1989;320:1592\u20137.","journal-title":"N Engl J Med"},{"key":"4700_CR21","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","volume":"41","author":"GM Fenichel","year":"1991","unstructured":"Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT 3rd, Griggs RC, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991;41:1874\u20137.","journal-title":"Neurology"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-021-04700-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T16:54:15Z","timestamp":1633020855000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04700-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4700"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04700-z","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"30 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective longitudinal study conducted as part of the STRIDE registry. Approval by the Swedish Ethics Committee and signed informed consent were obtained prior to inclusion in the STRIDE registry. For all subjects below the age of 18\u00a0years, informed consent was signed by the parents\/guardians.All examinations and parameters stated in the methods that were used in the study were performed in accordance with the relevant regulations and international guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Assoc. prof\u00a0Anna-Karin Kroksmark has held oral presentations for PTC and professor M\u00e1r Tulinius has provided medical consulting\u00a0services as well as held oral presentations for PTC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"837"}}